Recognized globally as an expert in schizophrenia, neurocognition and pharmacologic treatment of cognitive impairment, Dr. Keefe has been instrumental in hundreds of cognition-related research projects. Below are links to Dr. Keefe’s articles and other published works that comprise his scientific library.
Vigen C., Mack W., Keefe R., Sano M., Sultzer D., Stroup T. S., Dagerman K., Hsiao J., Lebowitz B., Lyketsos C., Tariot P., Zheng L., Schneider L., Cognitive Effects of Atypical Antipsychotic Medications in Patients With Alzheimer’s Disease: Outcomes From CATIE-AD. AJP in Advance, May 15, 2011.
Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophrenia Bulletin, 1999; 25: 201-222.
Keefe RSE, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn M, Lewine RRJ, Yurgelun-Todd D, Gur RC, Tohen M, Tollefson GM, Sanger TM, Lieberman JA, and the HGDH Research Group. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized double-blind trial of olanzapine versus low-dose haloperidol. American Journal of Psychiatry, 2004; 161: 985-995.
Keefe RSE¸ Goldberg TE, Harvey PD, Gold JM, Poe M, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia Research, 2004; 68: 283-297.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 2005; 353: 1209-1223.
Buchanan RW, Davis M, Goff D, Green MF, Keefe RSE, Leon A, Nuechterlein K, Laughren T, Levin R, Stover E, Fenton W, Marder, S. A Summary of the FDA-NIMH-MATRICS workshop on clinical trial designs for neurocognitive drugs for schizophrenia. Schizophrenia Bulletin, 2005; 31: 5-19.
Keefe RSE, Young CA, Rock SL, Purdon SE, Gold JM, Breier A. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophrenia Research, 2006; 81: 1-15.
Keefe RSE, Poe M, Walker TM, Harvey PD. The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome. Journal of Clinical and Experimental Neuropsychology, 2006; 28: 260-269.
Keefe RSE, Poe M, Walker TM, Kang JW, Harvey PD. The Schizophrenia Cognition Rating Scale (SCoRS): Interview-based assessment and its relationship to cognition, real-world functioning and functional capacity. American Journal of Psychiatry, 2006; 163: 426-432.
Keefe RSE, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, Meltzer HY, Green MF, Miller DD, Canive JM, Adler LW, Manschreck TC, Swartz M, Rosenheck R, Perkins DO, Walker TM, Stroup TS, McEvoy JP, Lieberman JA. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006, 31: 2033-2046.
Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, and Lieberman JA for the CATIE Investigators and the Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry, 2007; 64: 633-647.
Keefe RSE, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: A randomized, double-blind 52 week comparison. The American Journal of Psychiatry, 2007; 164: 1061-1071.
Goff DC, Keefe RSE, Citrome L, Davy K, Krystal J, Large C, Volayka J, Webster EL. Lamotrigine as add-on therapy in schizophrenia: Results of two placebo-controlled trials. Journal of Clinical Psychopharmacology, 2007; 27: 582-589.
Keefe RSE, Malhotra AK, Meltzer H, Kane JM, Buchanan RW, Murthy A, Sovel M, Li, C, Goldman R. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: Significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology, 2008; 33: 1217-1228.
Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch D, Cohen J, Essock S, Fenton WS, Frese FJ, Gold JM, Goldberg T, Heaton R, Keefe RSE, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger D, Young AS, Zalcman S, Marder SR. The MATRICS consensus cognitive battery: Part 1. Test selection, reliability, and validity. The American Journal of Psychiatry, 2008; 165: 203-213.
Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RSE, Mesholam-Gately R, Mintz J, Seidman LJ, Stover E, Marder SR. The MATRICS consensus cognitive battery: Part 2. Co-norming and standardization. The American Journal of Psychiatry, 2008; 165: 214-220.
Green MF, Nuechterlein KH, Kern RS, Baade LE, Fenton WS, Gold JM, Keefe RSE, Mesholam-Gately R, Seidman LJ, Stover E, Marder SR. Functional co-primary measures for clinical trials in schizophrenia: Results from the MATRICS psychometric and standardization study. The American Journal of Psychiatry, 2008; 165: 221-228.
Hill SK, Sweeney JA, Hamer RM, Keefe RSE, Perkins DO, Gu H, McEvoy JP, Lieberman JA. Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. Journal of International Neuropsychological Society, 2008; 14: 209-221.
Keefe, RSE, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.Schizophr Res. 2011 Feb;125(2-3):161-8